RE:RE:RE:RE:RE:RE:RE:RE:RE:Patient #16, #17 & #18Correct Yajne
This was announced in the news release for the 7th US site!
To date, Study II has enrolled and provided the primary study treatment for 20 patients (including three patients from Phase Ib study treated at the Therapeutic Dose) for a total of 23 patients.
Shawn Shirazi, PhD, Chief Executive Officer of Theralase®, stated, “It is exciting to see Theralase® clear another hurdle by treating the first patient in the US and move one step closer to achieving its next milestone of enrolling and treating twenty-five patients in early 2021. Once completed, Theralase® plans to submit the clinical assessment data on the first twenty-five patients treated in Study II to the FDA for consideration of Break Through Designation (“BTD”) status.”
Yajne wrote
One patient treated in US to date although I can't find the release at the moment to confirm that. A huge surprise for me and likely others since they have avoided major hospitals for their US based CSS's which I thought would minimize COVID delays. If the snail could only crawl even slower.... CAinPlap wrote: We have several US sites approved but do we have any US patients treated yet? What is the bottleneck in getting new patients treated? Doctor training? Willing paticipants? Would it be realistic to expect one patient per site per month? If not, why?